Page 108 - 《中国药房》2023年22期

immunoglobulin plus prednisolone for prevention of coro‐ Three linked vasculopathic processes characterize Kawasaki
nary artery abnormalities in severe Kawasaki disease disease：a light and transmission electron microscopic
（RAISE study）：a randomised，open-label，blinded- study[J]. PLoS One，2012，7（6）：e38998.
endpoints trial[J]. Lancet，2012，379（9826）：1613-1620. [23] NAOE S，TAKAHASHI K，MASUDA H，et al. Kawasaki
[15] OGATA S，OGIHARA Y，HONDA T，et al. Corticosteroid disease：with particular emphasis on arterial lesions[J].
pulse combination therapy for refractory Kawasaki disease： Acta Pathol Jpn，1991，41（11）：785-797.
a randomized trial[J]. Pediatrics，2012，129（1）：e17-e23. [24] MUTA H，ISHII M，YASHIRO M，et al. Late intravenous
[16] TREMOULET A H，JAIN S，JAGGI P，et al. Infliximab immunoglobulin treatment in patients with Kawasaki
for intensification of primary therapy for Kawasaki disease[J]. Pediatrics，2012，129（2）：e291-e297.
disease：a phase 3 randomised，double-blind，placebo- [25] OKADA Y，SHINOHARA M，KOBAYASHI T，et al.
controlled trial[J]. Lancet，2014，383（9930）：1731-1738. Effect of corticosteroids in addition to intravenous gamma
[17] YOUN Y，KIM J，HONG Y M，et al. Infliximab as the globulin therapy on serum cytokine levels in the acute
first retreatment in patients with Kawasaki disease resis‐ phase of Kawasaki disease in children[J]. J Pediatr，2003，
tant to initial intravenous immunoglobulin[J]. Pediatr 143（3）：363-367.
Infect Dis J，2016，35（4）：457-459. [26] BROWN T J，CRAWFORD S E，CORNWALL M L，et al.
[18] HAMADA H，SUZUKI H，ONOUCHI Y，et al. Efficacy CD8 T lymphocytes and macrophages infiltrate coronary
of primary treatment with immunoglobulin plus ciclospo‐ artery aneurysms in acute Kawasaki disease[J]. J Infect
rin for prevention of coronary artery abnormalities in Dis，2001，184（7）：940-943.
patients with Kawasaki disease predicted to be at increased [27] DE GRAEFF N，GROOT N，OZEN S，et al. European
risk of non-response to intravenous immunoglobulin consensus-based recommendations for the diagnosis and
（KAICA）：a randomised controlled，open-label，blinded- treatment of Kawasaki disease：the SHARE initiative[J].
endpoints，phase 3 trial[J]. Lancet，2019，393（10176）： Rheumatology，2019，58（4）：672-682.
1128-1137. [28] ONOUCHI Y，SUZUKI Y，SUZUKI H，et al. ITPKC and
[19] PORTMAN M A，DAHDAH N S，SLEE A，et al. Etaner‐ CASP3 polymorphisms and risks for IVIG unresponsive‐
cept with IVIG for acute Kawasaki disease：a randomized ness and coronary artery lesion formation in Kawasaki
controlled trial[J]. Pediatrics，2019，143（6）：e20183675. disease[J]. Pharmacogenomics J，2013，13（1）：52-59.
[20] WANG Z P，CHEN F Y，WANG Y F，et al. Methylpred‐ [29] FURUKAWA S，MATSUBARA T，JUJOH K，et al.
nisolone pulse therapy or additional IVIG for patients with Peripheral blood monocyte/macrophages and serum tumor
IVIG-resistant Kawasaki disease[J]. J Immunol Res， necrosis factor in Kawasaki disease[J]. Clin Immunol
2020，2020：4175821. Immunopathol，1988，48（2）：247-251.
[21] BURNS J C，ROBERTS S C，TREMOULET A H，et al. [30] HIRONO K，KEMMOTSU Y，WITTKOWSKI H，et al.
Infliximab versus second intravenous immunoglobulin for Infliximab reduces the cytokine-mediated inflammation
treatment of resistant Kawasaki disease in the USA but does not suppress cellular infiltration of the vessel
（KIDCARE）：a randomised，multicentre comparative wall in refractory Kawasaki disease[J]. Pediatr Res，2009，
effectiveness trial[J]. Lancet Child Adolesc Health，2021， 65（6）：696-701.
5（12）：852-861. （收稿日期：2023-05-16 修回日期：2023-10-26）
[22] ORENSTEIN J M，SHULMAN S T，FOX L M，et al. （编辑：陈 宏）

· 2786 · China Pharmacy 2023 Vol. 34 No. 22 中国药房 2023年第34卷第22期